• Current Client Contact
  • Skip to primary navigation
  • Skip to content

Conway Homer, P.C.

Vaccine Injury Law Firm

Main navigation

  • About
  • Vaccine Injuries
    • All Vaccine Injuries
    • Acute Disseminated Encephalomyelitis (ADEM)
    • Anaphylaxis
    • Brachial Neuritis
    • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    • Idiopathic Thrombocytopenic Purpura (ITP)
    • Intussusception
    • Guillain-Barré Syndrome (GBS) & Flu Vaccine
    • Multiple Sclerosis (MS)
    • Narcolepsy
    • Optic Neuritis
    • Rheumatoid Arthritis (RA)
    • Sensorineural Hearing Loss (SNHL)
    • Shoulder Injury Related to Vaccine Administration (SIRVA)
    • Systemic Lupus Erythematosus (SLE)
    • Transverse Myelitis (TM)
  • Case Results
  • FAQ
  • Vaccine Injury Compensation Program
  • Blog
  • Contact Us
    Hablamos Español
  • Call Us at
    1 (855) 880-5324

July 28, 2016

Meningococcal Vaccine

What is the Meningococcal Vaccine? Meningococcal disease refers to any disease caused by meningococcus bacteria.  This bacteria is the leading cause of bacterial meningitis in children 2 through 18 years old in the United States.  It can also cause blood infections.  The two peak populations for meningococcal disease are in children younger than 2, and […]

What is the Meningococcal Vaccine?

Meningococcal disease refers to any disease caused by meningococcus bacteria.  This bacteria is the leading cause of bacterial meningitis in children 2 through 18 years old in the United States.  It can also cause blood infections.  The two peak populations for meningococcal disease are in children younger than 2, and young adults aged 15 to 24 years.  Currently, there are two types of meningococcal vaccines administered in the U.S. to prevent the spread of Meningococcal disease.  They are meningococcal conjugate vaccine (MCV4) and the meningococcal polysaccharide vaccine (MPSV4).

Who should receive a meningococcal vaccine?

The Centers for Disease Control and Prevention (CDC) has recommended routine vaccination of adolescents from 11 to 12 years of age with MCV4.  The CDC also recommends a booster before high school entry (at approximately age 15-16 years) as an effective strategy to reduce meningococcal disease incidence among adolescents and young adults.

MCV4 is the preferred vaccine for people who are 9 months through 55 years of age.  MPSV4 is recommended for adults older than 55.

How is the meningococcal vaccine administered?

For children and adults (2 to 55 years of age) MCV4 is administered as a single 0.5 ml dose intramuscularly and should be given at a 90-degree angle.  MPSV4 (older than 55 years of age) is administered 0.5 ml subcutaneously and should be given at a 45-degree angle.

Meningococcal Vaccine Packet Inserts:
Menactra®, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine – Packet Insert
Menomune® – A/C/Y/W-135, Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined – Packet Insert

Contact Us

Send us your contact info, and we’ll get in touch soon. Or, feel free to call us at 617-695-1990.

  • This field is for validation purposes and should be left unchanged.

Copyright © 2018 Conway Homer, P.C. · Terms of Use & Disclaimer · Website managed by Good2bSocial